Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

NCT06709495 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

63

Enrollment

OTHER

Sponsor class

Conditions

Sarcoma
Sarcoma, Ewing
Desmoplastic Small Round Cell Tumor
Refractory Sarcoma
Osteosarcoma
Rhabdomyosarcoma

Interventions

DRUG: PEEL-224
DRUG: Temozolomide
DRUG: Vincristine
BIOLOGICAL: Pegfilgrastim
BIOLOGICAL: Filgrastim

Sponsor

David S Shulman, MD

Collaborators

[object Object]